Guidelines for the Evaluation and Management of Heart Failure
John F. Williams, Thomas J. Ryan(Laing O'Rourke (United Kingdom)), Raymond J. Gibbons(Mayo Clinic), Milton Packer(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Michael R. Bristow, Bertram Pitt(Bayer (Germany)), LAURA F. WEXLER, Bernard J. Gersh(Mayo Clinic), Richard P. Lewis, Kim A. Eagle, Daniel J. Ullyot, James L. Ritchie(Facing Our Risk of Cancer Empowered), Timothy J. Gardner(Eagle Mount), Melvin D. Cheitlin, Michael B. Fowler(Michael & Associates), Gary S. Francis, Robert A. O’Rourke(Richard Wolf (Germany)), William L. Winters, Mark A. Hlatky, Carl V. Leier, Donald Hammer
Cited by 668
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies
|Circulation|1996|3.5k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k